

Didactic: COVID-19 Therapeutics Case discussions

10/6/2020



COVID-19 Therapeutics, updates as of 10/6/2020

Rupali Jain, PharmD UW Medicine rupali@uw.edu




- Review key data for the treatment of COVID-19
- Summarize National Institutes of Health and Infectious Diseases Society of America guidelines

https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-andmanagement/#toc-5

https://www.covid19treatmentguidelines.nih.gov/




COVID-19 Natural History





Manifestations: mild/moderate to severe disease



Therapeutics landscape



ASYMPTOMATIC: TEST POSITIVE; BUT NO SYMPTOMS

MILD: SIGNS/SYMPTOMS (FEVER, COUGH, SORE THROAT, MALAISE, HEADACHE, MUSCLE PAIN) BUT NO SHORTNESS OF BREATH, DYSPNEA, OR ABNORMAL CHEST IMAGING

MODERATE: LOWER RESPIRATORY DISEASE

CHEST IMAGING **OR** SATURATION OF O2 (SpO2) >94% ON ROOM AIR



<u>SEVERE ILLNESS</u>: RESP FREQUENCY > 30 BREATHS/MIN, SpO2 <94% on ROOM AIR, RATIO OF ARTERIAL PARTIAL PRESSURE OF OXYGEN TO FRACTION OF INSPIRED OXYGEN (PaO_2/FiO_2) <300 MMHG, OR LUNG INFILTRATES >50%



CRITICAL ILLNESS: RESPIRATORY FAILURE, SEPTIC SHOCK AND/OF MULTIPLE ORGAN DYSFUNCTION

Therapeutics landscape



HOME: ASYMPTOMATIC/ MILD DISEASE

Treatment: NO TREATMENT CLINICAL TRIALS

MODERATE:

IV REMDESIVIR? NO DEXAEMETHASONE



SEVERE:

- IV REMEDESIVIR
- DEXAMETHASONE
- CONVALSCENT PLASMA -?



CRITICAL ILLNESS

• IV REMDESIVIR

DEXAMETHASONE



Did not prevent symptomatic disease in patients with moderate or high risk exposures (HCQ vs placebo, 11.8% vs 14.3% p =0.35)¹

- HCQ group had more side effects: diarrhea, nausea, abdominal discomfort
- 66% were HCW

Did not prevent infections among HCW exposed to patients with COVID-19 (HCQ vs placebo, 6.3% vs 6.6% P >0.99)²

- Ended early for futility

Boulware, et al N Engl J Med 2020; 383:517-525
 Abella BS. JAMA Intern Med. Published online September 30, 2020.



Asymptomatic

- no additional laboratory testing and
- no specific treatment for persons with suspected or confirmed asymptomatic or presymptomatic SARS-CoV-2 infection (AIII).

Active area of research:

- Monoclonal Ab






Mild illness

- Most mildly ill patients can be managed in an ambulatory setting or at home through telemedicine or remote visits.
- All patients with symptomatic COVID-19 and risk factors for severe disease should be closely monitored.
- In some patients, the clinical course may rapidly progress.
- Active area of research:
- Monoclonal Ab
- IV Remdesivir





Monoclonal Antibodies




What are they?

- Monoclonal antibodies (mAbs) are produced by B cells and specifically target antigens
- protein made in the lab that bind to specific receptors or cells in the body
- A monoclonal antibody is made so that it binds to only one substance.
- They can be used alone or to carry drugs, toxins, or radioactive substances directly to cancer cells.


Protection With mAbs

Monoclonal antibody therapies are drugs that could provide a 'bridge' of immunity until vaccines are ready.

Without any antibodies, the coronavirus will bind to the ACE2 receptor on a human cell



The antibody acts as a blocker, preventing the virus from attaching



National Cancer Institute.

How do they help?

- have the potential to be used for both prevention and treatment of infection.
- Several products being evaluated
- Lilly product (LYCoV555)
 - Press report: viral load reduction and decreased rate of hospitalization and ER visits
- Regeneron (REGN 10933 and REGN10987)
 - REGN-COV2 rapidly reduced viral load through Day 7 in seronegative patients
- Limitations:
- unknown bioavailability of passively infused IgG in tissues affected by the disease, especially the lungs

https://investor.lilly.com/news-releases/news-release-details/lilly-announces-proof-concept-data-neutralizing-antibody-ly JAMA. 2020;324(2):131-132.

https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and



Therapeutics landscape









MODERATE: LOWER **RESPIRATORY DISEASE** (CHEST IMAGING OR SATURATION OF O2 (SpO2) >94% ON ROOM AIR)




Remdesivir (GS-5734)

- Adenosine nucleotide analogue prodrug
- Broad-spectrum against several RNA viruses⁽
- Requires phosphorylation for activation triphosphate form
- Competes for incorporation with adenosine triphosphate (ATP)
- Selectivity of ATP versus Remdesivir
 - Ebola RNA-dependent RNA polymerase \sim 4:1
 - RSV RNA-dependent RNA polymerase ~ 3:1
 - Human mitochondrial RNA polymerase \sim 500:1



IV Remdesivir - MODERATE



Treatment group

Is there Consensus?

IDSA:

In patients with COVID-19 admitted to the hospital without the need for supplemental oxygen and oxygen saturation >94% on room air, IDSA suggests against the routine use of remdesivir. (Conditional recommendation, Very low certainty of evidence)

NIH:

Recommendation for Patients With Mild or Moderate COVID-19

• There are insufficient data for the Panel to recommend either for or against the use of **remdesivir** in patients with mild or moderate COVID-19.



Therapeutics landscape




SEVERE ILLNESS: RESP FREQUENCY > 30 BREATHS/MIN, SpO2 <94% on ROOM AIR, RATIO OF ARTERIAL PARTIAL PRESSURE OF OXYGEN TO FRACTION OF INSPIRED OXYGEN (PaO₂/FiO₂) <300 MMHG, OR LUNG INFILTRATES >50%



CRITICAL ILLNESS: RESPIRATORY FAILURE, SEPTIC SHOCK AND/OF MULTIPLE ORGAN DYSFUNCTION

Concept of Using Convalescent Plasma to Treat COVID-19






Convalescent Plasma Through a National Expanded Access Program

- 20,000 patients enrolled nationwide
- Adults with severe, life-threatening disease
- No placebo arm
- Main outcomes were safety including data, SAEs at 4 hour and 7 days after transfusion
- The overall mortality rate was 8.6% at 7 days.
- therapy was associated with a low incidence (<1%) of serious transfusion-related events.

There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of **COVID-19 convalescent plasma** for the treatment of COVID-19.





https://doi.org/10.1101/2020.08.12.20169359; NIH guidelines


ACTT-1, preliminary


Randomized controlled trial IV Remdesivir x 10 days, any hospitalized pt with COVID-19

The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.

Majority of patients included were on supplmental oxygen







Subgroup	No. of Patients	Recovery Rate Ratio (95% CI)	
All patients	1059	⊢ → − 1	1.32 (1.12–1.55)
Geographic region			
North America	844	⊢	1.33 (1.11-1.59)
Europe	163	⊢ <u>∔</u> ●	1.40 (0.90-2.16)
Asia	52	► • • • • • • • • • • • • • • • • • • •	1.20 (0.65-2.22)
Race			
White	563	↓ ↓	1.39 (1.12-1.73)
Black	219		1.14 (0.81-1.61)
Asian	134	⊢ I	1.04 (0.68-1.57)
Other	143	• • • • • • • • • • • • • • • • • • • •	1.89 (1.15-3.10)
Ethnic group			
Hispanic or Latino	247		1.23 (0.88-1.72)
Not Hispanic or Latino	748	⊢	1.33 (1.10-1.61)
Age			
18 to <40 yr	119	↓↓	2.03 (1.31-3.15)
40 to <65 yr	558	⊢ <mark>¦ ●</mark> 1	1.16 (0.94-1.44)
≥65 yr	382	↓ 	1.37 (1.02-1.83)
Sex			
Male	682	⊢	1.31 (1.07-1.59)
Female	377	¦ ⊢+	1.38 (1.05-1.81)
Symptoms duration			
≤10 days	664	¦ ⊢+	1.28 (1.05-1.57)
>10 days	380	⊢	1.38 (1.05–1.81)
Baseline ordinal score			
4 (not receiving oxygen)	127	⊢	1.38 (0.94-2.03)
5 (receiving oxygen)	421	¦ ⊢	1.47 (1.17-1.84)
 (receiving high-flow oxygen or noninvasive mechanical ventilation) 	197	⊢	1.20 (0.79–1.81)
7 (receiving mechanical ventilation or ECMO)			0.95 (0.64–1.42)
		Placebo Better Remdesivir Better	

Η

Duration of therapy

IDSA: In patients on supplemental oxygen but not on mechanical ventilation or ECMO, the IDSA panel suggests treatment with five days of remdesivir rather than 10 days of remdesivir. (Conditional recommendation, Low certainty of evidence)

•Remark: In patients on mechanical ventilation or ECMO, the duration of treatment is 10 days.

<u>NIH</u>: Duration of Therapy for Patients Who Have Not Shown Clinical Improvement After 5 Days of Therapy

• There are insufficient data on the optimal duration of **remdesivir** therapy for patients with COVID-19 who have not shown clinical improvement after 5 days of therapy. In this group, <u>some experts</u> extend the total remdesivir treatment duration to up to 10 days (CIII).


Recommendations for Patients with COVID-19 Who Require Supplemental Oxygen

- The Panel recommends using **remdesivir** for 5 days or until hospital discharge, whichever comes first **(AI)**.
- If a patient who is on supplemental oxygen while receiving remdesivir *progresses* to requiring delivery of oxygen through a high-flow device, noninvasive ventilation, or invasive mechanical ventilation, or ECMO, the course of remdesivir should be completed.




Dex

- Open-label trial who were hospitalized with COVID-19
- Randomized to IV/PO dexamethasone 6mg/day or usual care
- Primary outcome death at 28 days



Symptoms >7 days did better with Dexamethasone

Figure S1: Effect of allocation to dexamethasone on 28-day mortality by other pre-specified baseline characteristics



- The Panel recommends using dexamethasone 6 mg per day for up to 10 days or until hospital discharge, whichever comes first, for the treatment of COVID-19 in hospitalized patients who are mechanically ventilated (AI) and in hospitalized patients who require supplemental oxygen but who are not mechanically ventilated (BI).
- •The Panel **recommends against** using **dexamethasone** for the treatment of COVID-19 in patients who do not require supplemental oxygen (AI).
- •If dexamethasone is not available, the Panel recommends using alternative glucocorticoids

Association Between Corticosteroids and 28-Day All-Cause Mortality in Each Trial

	ClinicalTrials.gov	Initial dose and		No. of deaths/total No. of patients		Odds ratio	Favors	Favors no	Weight,
Drug and trial	identifier	administration		Steroids	No steroids	(95% CI)	steroids	steroids	%
Dexamethasone							!		
DEXA-COVID 19	NCT04325061	High: 20 mg/d intr	2/7	2/12	2.00 (0.21-18.69)		•	→ 0.92	
CoDEX	NCT04327401	High: 20 mg/d intr	69/128	76/128	0.80 (0.49-1.31)			18.69	
RECOVERY	NCT04381936	Low: 6 mg/d orally	95/324	283/683	0.59 (0.44-0.78)			57.00	
Subgroup fixed e	effect			166/459	361/823	0.64 (0.50-0.82)			76.60
Hydrocortisone									
CAPE COVID	NCT02517489	Low: 200 mg/d intravenously		11/75	20/73	0.46 (0.20-1.04)		<u>.</u>	6.80
COVID STEROID	NCT04348305	Low: 200 mg/d int	6/15	2/14	4.00 (0.65-24.66)			▶ 1.39	
REMAP-CAP	NCT02735707	Low: 50 mg every	6 h intravenouslv	26/105	29/92	0.71 (0.38-1.33)			11.75
Subgroup fixed e	effect								19.94
Methylprednisolon	e					quivalencies			
Steroids-SARI	NCT04244591	High: 40 mg every	these dru	ugs to	dexam	ethasone 6	mg (oral 🔒		3.46
Overall (fixed effect) or intrave				enous	[IV]) ar	re:			100.0
P=.31 for heterogeneity; I ² =15.6% Pred			Inisone 40 mg						
Overall (random effects ^a)			Met	hylprednisolone 32 mg					
	Hyd				tisone 1	L60 mg		· · · · ·	_
			/					1	4
IAMA. Published online September 2, 2020.								(95% CI)	-U-

JAMA. Published online September 2, 2020. doi:10.1001/jama.2020.17023



- Monitor pts for hyperglycemia, secondary infections, psychiatric effects, avascular necrosis
- Steroids and influenza: not a great combination
 - Increased risk for prolonged viral shedding and worse outcomes
- Steroids may increase risk of reactivation of infections (Hepatitis B, herpes, strongyloidiasis, tuberculosis)

Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. *Cochrane Database Syst Rev.* 2016;3:CD010406. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/26950335</u>.



Therapeutics landscape



HOME: ASYMPTOMATIC/ MILD DISEASE

Treatment: NO TREATMENT CLINICAL TRIALS

MODERATE:

IV REMDESIVIR?

NO DEXAEMETHASONE

HOSPITALIZED WITH O2 REQUIREMENT

- IV REMEDESIVIR
- DEXAMETHASONE
- CONVALSCENT PLASMA -?

CRITICAL ILLNESS

- IV REMDESIVIR
- DEXAMETHASONE

Summary

- Emerging therapy for monoclonal Antibodies
- More definitive data for Steroids
- IV Remdesivir remains mainstay antiviral for hospitalized patient requiring O₂
- Convalescent Plasma is no longer routinely recommended







Anticoagulation

- What is the recommended VTE prophylaxis in patients with COVID-19?
- All hospitalized adults with COVID-19 should receive pharmacologic thromboprophylaxis.

https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation https://www.covid19treatmentguidelines.nih.gov/adjunctivetherapy/antithrombotic-therapy/





Vitamin C:

- Data are insufficient to recommend for or against the use
- Vitamin D:
- Data are insufficient to recommend for or against the use

